Rebus Bio acquires EEL Transcriptomics

By The Science Advisory Board staff writers

December 10, 2021 -- Rebus Bio, an Illumina Ventures-backed company, announced that it has acquired the intellectual property and related assay assets of EEL Transcriptomics, a privately held company that develops high-plex spatial transcriptomics with single-cell resolution.

Running the EEL assay on the Rebus Esper platform enables spatial transcriptomics with single-cell resolution and has the potential to scale to more than 5,000 genes. The technology is applicable to a wide range of sample types, according to the firm.

The EEL assay will be available for use on the Esper system through early access in the first half of 2022 and commercially available in June of 2022.

No terms of the agreement were disclosed.

New neoadjuvant platform helps inform combo immunotherapy selection for cancers
WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help...
Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator...
Scientists create atlas of mouse brain regions down to single cells
An atlas of the mouse cerebrum and primary motor cortex down to the level of single cells was published in a pair of papers on October 6 in Nature....
Bio-Techne launches multiplex spatial genomics assay
Bio-Techne has expanded its RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed,...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter